Ultime notizie per Azzurro Solutions (OTC:AZRS) Azioni

Azzurro Solutions Corp is a shell company. It is a development stage company and the company's business is the distribution of Bohemian crystal chandeliers produced in the Czech Republic.

AZZURRO SOLUTIONS CORP by AZZURRO SOLUTIONS CORP.

Azzurro Solutions Corp

Digital bank company Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) could show its continued growth in Latin America when the company reports first-quarter financial results after <a href="https://www.benzinga.com/earnings">market close on Tuesday.</a>
Earnings Estimates: Analysts expect the company to report first-quarter revenue of $3.14 billion, up from $2.74 billion in last year's first quarter, according to data<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0512"> from Benzinga Pro.</a>
The company missed analyst estimates in the third quarter, but has beaten estimates in six of the past 10 quarters.
Analysts expect the company to report earnings per share of 12 cents for the first quarter, up from nine cents per share in last year's first quarter. The company missed estimates in the fourth quarter, while beating estimates in five of the past 10 quarters.
Read Also: <a href="https://www.benzinga.com/insights/analyst-ratings/25/04/45007114/the-analyst-verdict-nu-holdings-in-the-eyes-of-5-experts">The Analyst Verdict: Nu Holdings In The Eyes Of 5 Experts</a>
Key Items to Watch: The digital bank company has expanded its cryptocurrency offerings in recent years and with the price of crypto soaring in late 2024 and early 2025, it will be interesting to see what the company says about crypto holdings and products.
Warren Buffett, who is a noted critic of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), holds shares of Nu Holdings in Berkshire Hathaway (NYSE-BRK-A)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>), <a href="https://www.benzinga.com/markets/cryptocurrency/22/05/27208096/warren-buffett-now-owns-bitcoin-heres-how-the-oracle-of-omaha-got-exposure-3">giving him exposure </a>to this company that has the leading cryptocurrency on its balance sheet.
Berkshire Hathaway lowered its holdings in Nu Holding in recent quarters, but still holds more than 40 million shares and around 0.8% of the company, with the <a href="https://www.cnbc.com/berkshire-hathaway-portfolio/">stake </a>valued at around $520 million.
Nu Holdings has posted strong growth in its key regions of Brazil, Mexico and Colombia. Investors and analysts will be looking to hear details on the company's growth in these regions and potential expansion elsewhere.
The company ended<a href="https://www.benzinga.com/25/02/43869101/nu-holdings-q4-earnings-revenue-miss-eps-in-line-22-customer-growth-and-more"> the fourth quarter </a>with over 114 million total global customers and as the third-largest financial institution by customer count in Brazil.
One potential item to watch for international expansion could be Nu Holdings'<a href="https://www.benzinga.com/news/financing/24/12/42535041/warren-buffett-gains-exposure-to-digital-banks-in-africa-south-america-heres-how"> equity stake in</a> Tyme Group, a digital bank company with exposure to Asia and Africa. Nu Holdings owns 10% of the company and could look to partner with the company or share more details with investors on what this stake could mean for the future.
The company could also comment on the global economies and how Latin America is growing and could have an opportunity to gain additional investments and exposure with trade wars being held between other countries, such as the U.S. and Mexico and the U.S. and China.
NU Price Action: Nu Holdings stock was up 1% to $13.08 on Monday versus a 52-week trading range of $9.01 to $16.15. Nu Holdings stock is up 21.8% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/education/25/05/45208955/warren-buffetts-giant-berkshire-portfolio-top-10-includes-banks-oil-and-apple">Warren Buffett&#8217;s Giant Berkshire Portfolio: Top 10 Includes Banks, Oil, And Apple</a></li>
</ul>
Photo: Diego Thomazini via Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Previews

Global

Trading Ideas

$BTC

Buffett-Backed Nu Holdings Preps Q1 Report As Crypto Bets Come Into View

WIIM

BLNK

Blink Charging shares are trading lower after the company reported worse-than-expected Q1 financial results.

Oppenheimer analyst Owen Lau maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Outperform and raises the price target from $269 to $293.

News

Price Target

Analyst Ratings

COIN

Oppenheimer Maintains Outperform on Coinbase Global, Raises Price Target to $293

XXII

22nd Century Group shares are trading higher following a Q1 revenue beat.

FOXA

Fox shares are trading higher after multiple firms raised their respective price targets on the stock.

CETX

Cemtrex shares are trading higher after the company announced its subsidiary secured an STQC certification from India's Ministry of Electronics and Information Technology.

Oppenheimer analyst Ian Zaffino maintains Kyndryl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) with a Outperform and raises the price target from $43 to $47.

Oppenheimer Maintains Outperform on Kyndryl Hldgs, Raises Price Target to $47

ONMD

OneMedNet shares are trading higher after the company announced it has expanded its capabilities within the DataVant Connect platform.

TLSA

Tiziana Life Sciences shares are trading higher after the company disclosed that the executive chairman and founder increased its stake in the organization with a 15,000 share purchase.

Just as the wine world has long relied on the 100-point Wine Score to guide consumers, a new cannabis-specific version is now hitting dispensary shelves in New York.
Certified Testing &amp; Data, an ISO-17025 accredited cannabis and hemp testing lab, has launched the Cannaleptic Rating, a 100-point product score that aims to simplify cannabis shopping by helping consumers quickly compare quality across brands and products.
<h3 class="wp-block-heading">Beyond THC: A New Standard For Judging Cannabis</h3>
While THC percentage has long dominated cannabis marketing, many industry insiders argue it's a poor proxy for quality or effects. Cannaleptic Rating offers an alternative, combining quantitative lab testing with qualitative consumer feedback across several categories: aroma, effects, appearance, taste, potency, terpene profile and contaminant analysis.
"Most cannabis consumers aren't cannabis experts, and they shouldn't have to be," said Aaron Riley, founder of Certified Testing &amp; Data. "When consumers spend their hard-earned money on cannabis, they should have an easy way to ensure they will receive the desired experience."
According to Riley, the system is meant to be cannabis's equivalent of the Wine Score; "a quick and simple way" to help buyers understand what they're getting, even when shopping across different dispensaries and brands.
<h3 class="wp-block-heading">Early Adopters In New York</h3>
The Cannaleptic Rating is launching with several well-known New York brands, including:
<ul class="wp-block-list">
<li>Florist Farms</li>
<li>Foy</li>
<li>Heavy Hitters</li>
<li>Jaunty</li>
<li>Soft Power Sweets</li>
<li>Umamii</li>
</ul>
Each product evaluated receives a score out of 100, visible on packaging or via participating dispensaries.
<h3 class="wp-block-heading">What Brands Are Saying</h3>
For brands participating in the pilot, the system offers not just credibility but also a chance to highlight premium processes.
"With the Cannaleptic Rating, consumers no longer have to guess," said Yon and Moose Haile, co-founders of Foy. "They can see firsthand that Foy is committed to setting a higher standard for cannabis excellence."
"Having a reliable rating system for our industry will be a major leap forward for customer satisfaction and industry legitimacy," added Mike McGregor, founder of Soft Power Sweets.
"Customers don't just have to take our word for it," said Nick Wilson, director of cultivation at Umamii. "Certified Testing &amp; Data is revolutionizing cannabis and setting the gold standard for how cannabis is tested and evaluated."
<h3 class="wp-block-heading">What's Next?</h3>
The Cannaleptic Rating is currently limited to New York but will expand to additional legal cannabis markets. According to Certified Testing &amp; Data, more brands are already in the onboarding pipeline.
Photo: Shutterstock

Cannabis

The Wine Score Of Weed? New 100-Point System Launches In New York

VRME

VerifyMe shares are trading lower following a Q1 revenue miss.

HYFM

Hydrofarm Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results.

Oppenheimer analyst Kristen Owen maintains Mosaic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) with a Outperform and raises the price target from $33 to $40.

Oppenheimer Maintains Outperform on Mosaic, Raises Price Target to $40

NPWR

NET Power shares are trading lower after the company reported a year-over-year decrease in Q1 EPS results.

PRSO

Peraso shares are trading lower after the company issued Q2 sales guidance below estimates.

Oppenheimer analyst Andreas Argyrides maintains Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Outperform and lowers the price target from $155 to $90.

KRRO

Oppenheimer Maintains Outperform on Korro Bio, Lowers Price Target to $90

<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13065407/Ispire-0513-900x600-1.png" alt="" class="wp-image-12845" style="width:902px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13065407/Ispire-0513-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13065407/Ispire-0513-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13065407/Ispire-0513-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The American vaping company with strong Chinese ties reported its revenue fell 12.7% in the three months to March, as it rushes to set up a new manufacturing facility in Malaysia
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Ispire's revenue fell and its loss widened in its latest fiscal quarter, as it overhauled its operation to reduce exposure to the U.S.-China trade war</li>
<li>The company is rushing to open a new factory in Malaysia, mirroring similar moves by other vaping companies to diversify their production away from China</li>
</ul>
A landmark trade deal between the U.S. and China lit a fire under U.S.-traded Chinese stocks on Monday, but you would never know from looking at shares of&nbsp;Ispire Technology Inc.&nbsp;(ISPR.US). Perhaps the vaping company would like it that way, since it's trying hard to convince investors it's a Los Angeles-based, U.S. entity, despite its strong China ties.
The reality is that Ispire is still quite reliant on China, which currently supplies most of its vaping hardware from its self-owned subsidiary in the Southern boomtown of Shenzhen. But the company is moving quickly to reduce those China ties, and provided a detailed update of its plans to move a major portion of its production to a new facility in Malaysia in its&nbsp;<a href="https://www.prnewswire.com/news-releases/ispire-technology-inc-reports-financial-results-for-fiscal-third-quarter-2025-302451490.html">latest quarterly results</a>&nbsp;announced on Monday.
Co-CEO Michael Wang also detailed a broader scramble by vaping product makers in general to move production out of China to lower exposure to potential U.S. tariffs in the ongoing trade war. He said that movement includes a couple of Ispire's competitors trying to set up factories in Vietnam, while others move to Indonesia.
"In this industry, literally 99.99% of vaping devices up to, say, two years ago were made in China," Wang said on Ispire's earnings call to discuss the latest results for the three months to March, its third fiscal quarter. "Today, there is a little bit of diversification in terms of country of origin, but still well over 90% of products are made in China."
Trade wars aside, Ispire is also being dogged by its own internal issues, which may explain why its stock fell 3% on Monday after it released its latest report. That contrasts sharply with a 3.4% rally for the MSCI China Index, as investors cheered a sharp reduction in tariffs imposed by the U.S. and China on each other's products for 90 days while they try to hammer out details of a new, longer-term trade deal.
Ispire's issues include declining revenue, high accounts receivable, margins that are well below its global peers, and ongoing losses that are only getting larger. Adding to the problems are earlier company hype about the potential of the cannabis vaping market, which led it to predict that sales of related products could help to drive its overall revenue to $1 billion by 2027 and $2 billion by 2029.
Such astronomic heights would require breakneck revenue growth, which was hardly what Ispire delivered in its latest results. Instead, the company reported its revenue fell 12.7% in the three months to March to $26.2 million from $30 million a year earlier – making the $1 billion revenue forecast look almost laughable.
The company provided a few updates on its cannabis business on its earnings call, including the launch of a new device called Sprout in a new partnership with a company called Raw Garden. But, probably wisely, it refrained from providing any inflated revenue forecasts for the business. Instead, Wang characterized his company as being in a "restructuring and manufacturing transitional period," which includes moving some of its manufacturing to Malaysia and also weaning itself from lower-quality customers who were driving up its accounts receivable to dangerously high levels.
<h4 class="wp-block-heading">Back to basics</h4>
Ispire has repeatedly drawn attention to its growing accounts receivables in earlier reports, showing both the company and investment community were worried about the trend. Against that backdrop, it said it recorded a milestone in the latest quarter by reducing its accounts receivables for the first time in its history. Specifically, it said the figure dropped to $60.4 million by the end of March from $67.7 million three months earlier.
We should point out the newest amount is still more than double the company's latest quarterly revenue. Still, the reduction shows Ispire realizes it can't just sell products to deadbeat customers who never pay their bills. Such deadbeats are eating into the company's cash, which plunged about 40% to $23.5 million at the end of March from $39.5 million a year ago.
As we've previously noted, the other focus for Ispire was its ongoing efforts to set up a new production facility in Malaysia to lower its geopolitical risk. On that front, Wang said Ispire recently received an interim license to manufacture nicotine products in Malaysia and anticipates getting a final license in the next few months. He added the facility is designed to eventually house up to 80 production lines.
"We have made significant strides as we are transitioning our manufacturing to&nbsp;Malaysia, effectively de-risking our production strategy for the current geopolitical climate," Wang said. "During the third fiscal quarter, in an effort to further streamline our operations and increase margins, we moved a number of our daily functions to our Malaysian campus, which we anticipate will reduce our operating expenses by&nbsp;$8 million&nbsp;annually."
Growing expenses are indeed a problem for the company. Its gross profit fell 21.3% during the quarter, dragging down its gross margin to 18.2% from 20.4%. Both margin figures are well behind rival&nbsp;RLX's&nbsp;(RLX.US) gross margin of 27.0% in last year's fourth quarter, showing just how much work Ispire needs to do to become more efficient. At the same time, Ispire's operating expenses rose 30.5% year-on-year to $15.4 million in the latest quarter, as it blamed factors like stock-based compensation, bad-debt expense and one-off severance costs.
That combination of falling revenue and rising expenses caused Ispire's net loss to widen to $10.9 million in the latest quarter from $5.9 million a year earlier.
The company held out a glimmer of hope for investors by saying that benefits from its restructuring in North America – which accounts for about a third of sales – will start to show up in its next quarterly report for the three months to June.
Investors seem to be losing patience with the company, with its shares down about 50% over the last year to trade at just under $3 – less than half their IPO price of $7 in 2023. At that level the stock now trades at depressed price-to-sales (P/S) ratio of just 1.14, a small fraction of the 6.94 for RLX, and a similar 6.90 for Hong Kong-listed rival&nbsp;Smoore International&nbsp;(6969.HK).

Equities

Opinion

Markets

This Cannabis Stock Sits Out The Rally Sparked By US-China Deal

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Orchestra BioMed shares are trading higher after the company reported better-than-expected Q1 sales results.

VCIG

VCI Global shares are trading higher following a year-over-year increase in FY24 sales results.

Oppenheimer analyst Andreas Argyrides maintains ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Outperform and lowers the price target from $15 to $9.

PRQR

Oppenheimer Maintains Outperform on ProQR Therapeutics, Lowers Price Target to $9

Azzurro Solutions

Comments

Azzurro Solutions

Notizie

Ultime notizie per Azzurro Solutions (OTC:AZRS) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO